Analysts expect that Halliburton (NYSE:HAL) will announce $3.20 billion in sales for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Halliburton’s earnings. The highest sales estimate is $3.22 billion and the lowest is $3.15 billion. Halliburton reported sales of $5.19 billion in the same quarter last year, which indicates a negative year-over-year growth rate of 38.3%. The firm is scheduled to announce its next earnings results on Tuesday, January 19th.
On average, analysts expect that Halliburton will report full year sales of $14.43 billion for the current financial year, with estimates ranging from $14.41 billion to $14.54 billion. For the next fiscal year, analysts forecast that the company will report sales of $13.62 billion, with estimates ranging from $12.66 billion to $14.46 billion. Zacks’ sales calculations are an average based on a survey of analysts that follow Halliburton.
Halliburton (NYSE:HAL) last posted its quarterly earnings results on Monday, October 19th. The oilfield services company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.03. The business had revenue of $2.98 billion for the quarter, compared to analysts’ expectations of $3.12 billion. Halliburton had a positive return on equity of 11.10% and a negative net margin of 26.60%. The firm’s quarterly revenue was down 46.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.34 earnings per share.
Several equities analysts recently issued reports on HAL shares. HSBC raised their price target on Halliburton from $9.50 to $13.70 and gave the company a “hold” rating in a report on Wednesday, July 22nd. Credit Suisse Group increased their target price on Halliburton from $11.75 to $12.00 and gave the company a “neutral” rating in a research note on Tuesday, October 20th. Wells Fargo & Company reissued a “hold” rating on shares of Halliburton in a research note on Monday, August 17th. Bank of America raised Halliburton from a “neutral” rating to a “buy” rating and increased their target price for the company from $14.00 to $18.00 in a research note on Tuesday, July 21st. Finally, Royal Bank of Canada increased their target price on Halliburton from $14.00 to $16.00 and gave the company an “outperform” rating in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Halliburton currently has an average rating of “Hold” and a consensus target price of $13.24.
Originally developed to create oxygen on Mars… this technology is now found at facilities run by Ikea, as well as 25 Fortune 100 companies like Walmart and AT&T. Will the IPO stock behind it soar?
Halliburton stock opened at $14.33 on Friday. The business’s 50-day simple moving average is $12.51 and its 200 day simple moving average is $13.18. The stock has a market cap of $12.67 billion, a price-to-earnings ratio of -2.88, a P/E/G ratio of 2.88 and a beta of 2.71. Halliburton has a 12-month low of $4.25 and a 12-month high of $25.47. The company has a quick ratio of 1.64, a current ratio of 2.30 and a debt-to-equity ratio of 1.85.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 23rd. Stockholders of record on Thursday, December 3rd will be issued a dividend of $0.045 per share. The ex-dividend date of this dividend is Wednesday, December 2nd. This represents a $0.18 dividend on an annualized basis and a dividend yield of 1.26%. Halliburton’s dividend payout ratio (DPR) is currently 14.52%.
Several institutional investors have recently bought and sold shares of HAL. Great West Life Assurance Co. Can raised its holdings in shares of Halliburton by 1,140.4% during the 3rd quarter. Great West Life Assurance Co. Can now owns 10,056,126 shares of the oilfield services company’s stock worth $12,748,000 after buying an additional 9,245,437 shares in the last quarter. FMR LLC raised its holdings in shares of Halliburton by 231.6% during the 2nd quarter. FMR LLC now owns 4,697,996 shares of the oilfield services company’s stock worth $60,980,000 after buying an additional 3,281,131 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its holdings in shares of Halliburton by 261.3% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,423,232 shares of the oilfield services company’s stock worth $29,200,000 after buying an additional 1,752,460 shares in the last quarter. Sanders Capital LLC raised its holdings in shares of Halliburton by 5.2% during the 2nd quarter. Sanders Capital LLC now owns 23,692,943 shares of the oilfield services company’s stock worth $348,751,000 after buying an additional 1,171,025 shares in the last quarter. Finally, Morgan Stanley raised its holdings in shares of Halliburton by 30.8% during the 3rd quarter. Morgan Stanley now owns 3,762,152 shares of the oilfield services company’s stock worth $45,335,000 after buying an additional 885,000 shares in the last quarter. 71.49% of the stock is owned by institutional investors.
About Halliburton
Halliburton Co engages in the provision of services and products to the energy industry related to the exploration, development, and production of oil and natural gas. It operates through the following segments: Completion and Production, and Drilling and Evaluation. The Completion and Production segment delivers cementing, stimulation, intervention, pressure control, specialty chemicals, artificial lift, and completion services.
Recommended Story: How is an ETF different from a mutual fund?
Get a free copy of the Zacks research report on Halliburton (HAL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle
October 2, 2020, may not rank as one of those “where were you when” moments. But when news broke that the President of the United States and the First Lady tested positive for the novel coronavirus, there was certainly a sense that we were living through a historical moment (as if we already were not).
Over the following days, several biotech and pharmaceutical companies took the headlines. However, these weren’t the vaccine stocks that investors have committed to memory. These were companies that are leading the race for antiviral therapeutics.
And with a very high profile proof of concept, therapeutics may have had their moment. It’s far too early to say whether these drugs truly carry the answer. But from the outset of the pandemic, there has been a feeling that therapeutics may carry the ultimate solution to neutralizing the most severe effects of the novel coronavirus.
As you might expect, there is no shortage of companies in the therapeutic discussion. In this special presentation, we’re highlighting seven companies that you should be paying close attention to. If therapeutics nudge ahead of a vaccine, these stocks are likely to make strong upward moves.
View the “7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle”.
